SCHEMBL395281

SCHEMBL395281

O=C(CCc1c[nH]c2ccccc12)N/N=C/c1ccc(F)cc1

nearest known ligand 0.83

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.83
ALDH1A1 P00352 5/20 0.80
LMNA P02545 2/20 0.80
MAPT P10636 8/20 0.76
KMT2A Q03164 5/20 0.76
MEN1 O00255 4/20 0.76
KDM4E B2RXH2 2/20 0.76
GFER P55789 1/20 0.76
POLB P06746 3/20 0.68
THRB P10828 1/20 0.68
GAA P10253 3/20 0.60
L3MBTL1 Q9Y468 1/20 0.60
NPSR1 Q6W5P4 1/20 0.60
GLA P06280 1/20 0.54
SIRT1 Q96EB6 1/20 0.53
HPGD P15428 1/20 0.52
HTT P42858 1/20 0.52
RECQL P46063 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL393675 0.91 FAAH (1.00) FAAHALDH1A1LMNAMAPTKMT2A
SCHEMBL393680 0.89 FAAH (0.83) FAAHALDH1A1LMNAMAPTKMT2A
SCHEMBL393982 0.89 FAAH (0.65) FAAHALDH1A1LMNAMAPTKMT2A
SCHEMBL13381133 0.89 ALDH1A1 (1.00) FAAHALDH1A1LMNAMAPTKMT2A
SCHEMBL393500 0.88 MAPT (0.81) FAAHALDH1A1LMNAMAPTKMT2A
SCHEMBL391199 0.87 FAAH (0.76) FAAHALDH1A1LMNAMAPTKMT2A
SCHEMBL393998 0.86 FAAH (0.78) FAAHALDH1A1LMNAMAPTKMT2A
SCHEMBL394413 0.84 FAAH (0.72) FAAHALDH1A1LMNAMAPTKMT2A
SCHEMBL395724 0.83 FAAH (0.76) FAAHALDH1A1LMNAMAPTKMT2A
SCHEMBL24863352 0.81 FAAH (0.70) FAAHALDH1A1LMNAMAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101649-B2 N-acylhydrazone derivatives useful as modulators of nicotinic acetylcholine receptors NEUROSEARCH A/S (DK) 2012-01-24 US disclosed
US-8101649-B2 N-acylhydrazone derivatives useful as modulators of nicotinic acetylcholine receptors NEUROSEARCH A/S (DK) 2012-01-24 US disclosed
US-8101649-B2 N-acylhydrazone derivatives useful as modulators of nicotinic acetylcholine receptors NEUROSEARCH A/S (DK) 2012-01-24 US disclosed
US-20100280092-A1 N-ACYLHYDRAZONE DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS NEUROSEARCH A/S (DK) 2010-11-04 US disclosed
US-20100280092-A1 N-ACYLHYDRAZONE DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS NEUROSEARCH A/S (DK) 2010-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100280092-A1 N-ACYLHYDRAZONE DERIVATIVES USEFUL AS MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS CHRNA3, CHRNA6, CHRNA2 FAAH 184/4885ALDH1A1 671/4885LMNA 2872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.